menu
    • menu

    Company profile for HighTide Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in Shenzhen, China, HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company...
    Founded in Shenzhen, China, HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HighTide TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    18B-102, Zhonghaixin, Ganli 2nd Road, Longgang District, Shenzhen, 518112
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hightidetx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HTD1801 Shows 52-Week Efficacy in Ph3 Type 2 Diabetes Trials
    HTD1801 Shows 52-Week Efficacy in Ph3 Type 2 Diabetes Trials

    31 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-31/htd1801-a-first-in-class-anti-inflammatory-metabolic-modulator-demonstrates-durable-52-week-efficacy-and-safety-in-two-phase-iii-trials-in-type-2-di

    PHARMIWEB
    31 Oct 2025
    Share Share
    Hightide Therapeutics Presents Phase 3 Data for Type 2 Diabetes
    Hightide Therapeutics Presents Phase 3 Data for Type 2 Diabetes

    17 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-17/easd-2025-hightide-therapeutics-announces-oral-presentation-of-phase-3-data-in-patients-with-type-2-diabetes

    PHARMAWEB
    17 Sep 2025
    Share Share
    Metabolic drug developer HighTide Therapeutics eyes $36M raise with HK IPO
    Metabolic drug developer HighTide Therapeutics eyes $36M raise with HK IPO

    14 Dec 2023

    // ENDPTS

    https://endpts.com/metabolic-drug-developer-hightide-therapeutics-files-for-hk-ipo-seeking-to-raise-36m/

    ENDPTS
    14 Dec 2023
    Share Share
    HighTide Therapeutics rides NASH R&D wave with a $107M raise
    HighTide Therapeutics rides NASH R&D wave with a $107M raise

    05 Jan 2023

    // ENDPTS

    https://endpts.com/hightide-therapeutics-raises-107-million-to-fund-nash-and-diabetes-studies/

    ENDPTS
    05 Jan 2023
    Share Share
    HighTide Therapeutics Raises $107 Million in Series C/C+ Financing
    HighTide Therapeutics Raises $107 Million in Series C/C+ Financing

    05 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hightide-therapeutics-raises-107-million-in-series-cc-financing-to-advance-innovative-pipeline-and-business-collaborations-301713616.html

    PR NEWSWIRE
    05 Jan 2023
    Share Share
    HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801
    HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

    15 Dec 2022

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hightide-therapeutics-and-quotient-sciences-announce-agreement-to-conduct-a-14c-human-adme-program-for-htd1801-301704039.html

    PR NEWSWIRE
    15 Dec 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search